PowerShares DB G10货币嘉实基金 DBV 深 沪
已收盘 03-03 16:00:00 美东时间
25.41
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 25.41
- 总市值 762.30万
- 52周最高 28.2072
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 24.25
- 委 比 0.00%
- 总股本 30.00万
- 历史最高 28.2072
- 量 比 0
- 振 幅 0.00%
- 历史最低 19.8672
- 每 手 1
- 风险率 0.05%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多DBV Technologies Launches $150M At-The-Market Offering Program
DBV Technologies Establishes an At-The-Market (ATM) Program on NasdaqDBV Technologies (TRQX:DBVp) (the "Company"), a clinical-stage biopharmaceutical company, today announced that it has filed a prospectus supplement
09-06 04:34
DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq
DBV Technologies, a clinical-stage biopharmaceutical company, has announced the establishment of an at-the-market (ATM) program on the Nasdaq Capital Market, allowing it to offer and sell up to $150 million in American Depositary Shares (ADS). The proceeds will primarily support activities related to the Biologics License Application (BLA) for VIASKIN® Peanut patch in toddlers aged 1-3 years, as well as advance the development of other product ca...
09-05 20:30
DBV Technologies to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
DBV Technologies announced that CEO Daniel Tassé will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025. The event will be webcast live and available on the Company’s Investors website for 90 days. DBV is developing the VIASKIN® patch for treating food allergies through epicutaneous immunotherapy, targeting millions affected by this condition. The company focuses on clinical trials...
09-03 20:30
DBV Technologies Reports Second Quarter and Half-Year 2025 Financial Results
DBV Technologies reported its Q2 2025 financial results, showing a net loss of $69.0 million for the first half of the year, compared to $60.5 million in 2024. Operating income decreased by $2.2 million due to reduced French research tax credits, while operating expenses rose by 7.5% due to increased R&D activities. The company raised $306.9 million in financing to advance its Viaskin Peanut patch, with $125.5 million received in April 2025. Cas...
07-29 20:08
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
DBV Technologies issued a half-year report on its liquidity contract with ODDO BHF as of June 30, 2025. The liquidity account included 210,069 DBV shares and €171,301.08. Since the contract's implementation on July 1, 2018, assets totaled 41,159 shares and €432,367.25. Between January 1 and June 30, 2025, 2,204 buy and 2,398 sell transactions occurred, involving 1.16 million shares and €1.49 million in purchases, and 1.21 million shares and €1.56...
07-28 20:30
DBV Technologies Announces Appointment of James Briggs as Chief Human Resources Officer
DBV Technologies appoints James Briggs as Chief Human Resources Officer, succeeding Caroline Daniere. Briggs, with extensive experience in human capital and organizational transformation, will lead the company's transition from a development-stage biotech to a commercial organization. He previously served as a Partner at East Bay Human Capital and held executive roles at MNG Health, Ciox Health, and Ikaria Inc. Briggs, who holds a Master's in Hum...
07-22 20:30
DBV Technologies Announces It Has Screened The First Subject In COMFORT Toddlers Supplemental Safety Study In Peanut Allergic Toddlers 1 – 3 Years Old
DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years OldFirst subject screened at the Respiratory Medicine Research Institute of Michigan
06-26 04:16
DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old
DBV Technologies announces the first subject screened in its COMFORT Toddlers supplemental safety study for peanut-allergic children aged 1–3. Conducted at Michigan's Respiratory Medicine Research Institute, the study will enroll approximately 480 subjects across 80–90 sites in the U.S., Canada, Australia, UK, and Europe. COMFORT Toddlers is a Phase 3 double-blind, placebo-controlled trial aiming to enhance safety and efficacy data from the EPITO...
06-25 20:15
DBV Technologies to Participate in Upcoming EAACI Congress 2025
DBV Technologies will participate in the EAACI Congress 2025 in Glasgow, presenting two posters, hosting a symposium, and exhibiting. They will share data on reduced accidental peanut reaction rates in Year 2 of the EPITOPE trial and results from the APTITUDE study on diagnosing non-IgE-mediated cow’s milk allergy. The symposium, "Peanut Allergy: Recent Research Highlights," will discuss epicutaneous immunotherapy and the allergist-patient relati...
06-12 20:05
DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting
DBV Technologies held its Combined General Meeting in Châtillon, France, chaired by Michel de Rosen. Shareholders approved all resolutions submitted by the Board of Directors. The company, focused on developing treatments for food allergies using its Viaskin™ technology, is headquartered in France with North American operations in Warren, NJ. Its shares trade on Euronext Paris and Nasdaq.
06-11 20:30
